Maravai LifeSciences Holdings Inc [MRVI] stock prices are up 7.31% to $7.63 at the moment. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The MRVI shares have gain 3.53% over the last week, with a monthly amount drifted -5.22%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Maravai LifeSciences Holdings Inc [NASDAQ: MRVI] stock has seen the most recent analyst activity on August 28, 2024, when Wells Fargo initiated its Overweight rating and assigned the stock a price target of $10. Previously, Morgan Stanley downgraded its rating to Equal-Weight on August 13, 2024, and dropped its price target to $10. On April 10, 2024, Craig Hallum initiated with a Buy rating and assigned a price target of $15 on the stock. BofA Securities upgraded its rating to a Buy and decreased its price target to $8 on December 12, 2023. KeyBanc Capital Markets downgraded its rating to a Sector Weight. Credit Suisse downgraded its rating to Neutral for this stock on May 23, 2023, and downed its price target to $14. In a note dated May 09, 2023, Goldman downgraded an Neutral rating on this stock.
The stock price of Maravai LifeSciences Holdings Inc [MRVI] has been fluctuating between $4.52 and $11.56 over the past year. Currently, Wall Street analysts expect the stock to reach $19 within the next 12 months. Maravai LifeSciences Holdings Inc [NASDAQ: MRVI] shares were valued at $7.63 at the most recent close of the market. An investor can expect a potential return of 149.02% based on the average MRVI price forecast.
Analyzing the MRVI fundamentals
The Maravai LifeSciences Holdings Inc [NASDAQ:MRVI] reported sales of 278.58M for trailing twelve months, representing a surge of 6.51%. Gross Profit Margin for this corporation currently stands at 0.42% with Operating Profit Margin at -0.16%, Pretax Profit Margin comes in at 2.14%, and Net Profit Margin reading is -0.47%. To continue investigating profitability, this company’s Return on Assets is posted at -0.09, Equity is -0.3 and Total Capital is -0.03. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 1.21.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 7.21 points at the first support level, and at 6.79 for the second support level. However, for the 1st resistance point, the stock is sitting at 7.92, and for the 2nd resistance point, it is at 8.21.
Ratios To Look Out For
It’s worth pointing out that Maravai LifeSciences Holdings Inc [NASDAQ:MRVI]’s Current Ratio is 10.00. As well, the Quick Ratio is 9.28, while the Cash Ratio is 8.36. Considering the valuation of this stock, the price to sales ratio is 6.91, the price to book ratio is 2.47.
Transactions by insiders
Recent insider trading involved GTCR INVESTMENT XI LLC, Director, that happened on May 28 ’24 when 9.94 million shares were sold.
